REPORT ID 6654

Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Report 2017

Publish Date
26-Dec-17
Pages
109
Format
Electronic (PDF)

In this report, the Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Resistant Pseudomonas Aeruginosa Infections Drugs for these regions, from 2012 to 2022 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs market competition by top manufacturers/players, with Resistant Pseudomonas Aeruginosa Infections Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    ContraFect Corp
    Inhibrx LP
    Achaogen Inc
    LegoChem Biosciences Inc
    Melinta Therapeutics Inc
    Novartis AG
    AmpliPhi Biosciences Corp
    Biolytics Pharma
    Shionogi & Co Ltd

On the basis of product, this report displays the sales volum, revenue, product price, market share and growth rate of each type, primarily split into
    Semi-Synthetic Penicillin
    Cephalosporin
    Lactam Drugs
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic
    Home Care

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Report 2017
1 Resistant Pseudomonas Aeruginosa Infections Drugs Overview
    1.1 Product Overview and Scope of Resistant Pseudomonas Aeruginosa Infections Drugs
    1.2 Classification of Resistant Pseudomonas Aeruginosa Infections Drugs by Product Category
        1.2.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Sales) Comparison by Types (2012-2022)
        1.2.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Semi-Synthetic Penicillin
        1.2.4 Cephalosporin
        1.2.5 Lactam Drugs
        1.2.6 Others
    1.3 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market by Application/End Users
        1.3.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales (Volume) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Home Care
    1.4 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market by Region
        1.4.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 China Status and Prospect (2012-2022)
        1.4.3 Japan Status and Prospect (2012-2022)
        1.4.4 South Korea Status and Prospect (2012-2022)
        1.4.5 Taiwan Status and Prospect (2012-2022)
        1.4.6 India Status and Prospect (2012-2022)
        1.4.7 Southeast Asia Status and Prospect (2012-2022)
        1.4.8 Australia Status and Prospect (2012-2022)
    1.5 Asia-Pacific Market Size (Value and Volume) of Resistant Pseudomonas Aeruginosa Infections Drugs (2012-2022)
        1.5.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2022)
        1.5.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2022)

2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Competition by Players/Suppliers, Region, Type and Application
    2.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Competition by Players/Suppliers
        2.1.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs (Volume and Value) by Type
        2.2.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Type (2012-2017)
    2.3 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs (Volume) by Application
    2.4 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs (Volume and Value) by Region
        2.4.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Region (2012-2017)

3 China Resistant Pseudomonas Aeruginosa Infections Drugs (Volume, Value and Sales Price)
    3.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
        3.1.1 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
        3.1.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price Trend (2012-2017)
    3.2 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Type
    3.3 China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Application

4 Japan Resistant Pseudomonas Aeruginosa Infections Drugs (Volume, Value and Sales Price)
    4.1 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
        4.1.1 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
        4.1.3 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price Trend (2012-2017)
    4.2 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Type
    4.3 Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Application

5 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs (Volume, Value and Sales Price)
    5.1 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
        5.1.1 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
        5.1.3 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price Trend (2012-2017)
    5.2 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Type
    5.3 South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Application

6 Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs (Volume, Value and Sales Price)
    6.1 Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
        6.1.1 Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
        6.1.2 Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
        6.1.3 Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price Trend (2012-2017)
    6.2 Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Type
    6.3 Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Application

7 India Resistant Pseudomonas Aeruginosa Infections Drugs (Volume, Value and Sales Price)
    7.1 India Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
        7.1.1 India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
        7.1.2 India Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
        7.1.3 India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price Trend (2012-2017)
    7.2 India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Type
    7.3 India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Application

8 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs (Volume, Value and Sales Price)
    8.1 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
        8.1.1 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
        8.1.2 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
        8.1.3 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price Trend (2012-2017)
    8.2 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Type
    8.3 Southeast Asia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Application

9 Australia Resistant Pseudomonas Aeruginosa Infections Drugs (Volume, Value and Sales Price)
    9.1 Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
        9.1.1 Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
        9.1.2 Australia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
        9.1.3 Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price Trend (2012-2017)
    9.2 Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Type
    9.3 Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share by Application

10 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Players/Suppliers Profiles and Sales Data
    10.1 ContraFect Corp
        10.1.1 Company Basic Information, Manufacturing Base and Competitors
        10.1.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            10.1.2.1 Product A
            10.1.2.2 Product B
        10.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        10.1.4 Main Business/Business Overview
    10.2 Inhibrx LP
        10.2.1 Company Basic Information, Manufacturing Base and Competitors
        10.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            10.2.2.1 Product A
            10.2.2.2 Product B
        10.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        10.2.4 Main Business/Business Overview
    10.3 Achaogen Inc
        10.3.1 Company Basic Information, Manufacturing Base and Competitors
        10.3.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            10.3.2.1 Product A
            10.3.2.2 Product B
        10.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        10.3.4 Main Business/Business Overview
    10.4 LegoChem Biosciences Inc
        10.4.1 Company Basic Information, Manufacturing Base and Competitors
        10.4.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            10.4.2.1 Product A
            10.4.2.2 Product B
        10.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        10.4.4 Main Business/Business Overview
    10.5 Melinta Therapeutics Inc
        10.5.1 Company Basic Information, Manufacturing Base and Competitors
        10.5.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            10.5.2.1 Product A
            10.5.2.2 Product B
        10.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        10.5.4 Main Business/Business Overview
    10.6 Novartis AG
        10.6.1 Company Basic Information, Manufacturing Base and Competitors
        10.6.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            10.6.2.1 Product A
            10.6.2.2 Product B
        10.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        10.6.4 Main Business/Business Overview
    10.7 AmpliPhi Biosciences Corp
        10.7.1 Company Basic Information, Manufacturing Base and Competitors
        10.7.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            10.7.2.1 Product A
            10.7.2.2 Product B
        10.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        10.7.4 Main Business/Business Overview
    10.8 Biolytics Pharma
        10.8.1 Company Basic Information, Manufacturing Base and Competitors
        10.8.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            10.8.2.1 Product A
            10.8.2.2 Product B
        10.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        10.8.4 Main Business/Business Overview
    10.9 Shionogi & Co Ltd
        10.9.1 Company Basic Information, Manufacturing Base and Competitors
        10.9.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            10.9.2.1 Product A
            10.9.2.2 Product B
        10.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        10.9.4 Main Business/Business Overview

11 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Cost Analysis
    11.1 Resistant Pseudomonas Aeruginosa Infections Drugs Key Raw Materials Analysis
        11.1.1 Key Raw Materials
        11.1.2 Price Trend of Key Raw Materials
        11.1.3 Key Suppliers of Raw Materials
        11.1.4 Market Concentration Rate of Raw Materials
    11.2 Proportion of Manufacturing Cost Structure
        11.2.1 Raw Materials
        11.2.2 Labor Cost
        11.2.3 Manufacturing Expenses
    11.3 Manufacturing Process Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs

12 Industrial Chain, Sourcing Strategy and Downstream Buyers
    12.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industrial Chain Analysis
    12.2 Upstream Raw Materials Sourcing
    12.3 Raw Materials Sources of Resistant Pseudomonas Aeruginosa Infections Drugs Major Manufacturers in 2016
    12.4 Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders
    13.1 Marketing Channel
        13.1.1 Direct Marketing
        13.1.2 Indirect Marketing
        13.1.3 Marketing Channel Development Trend
    13.2 Market Positioning
        13.2.1 Pricing Strategy
        13.2.2 Brand Strategy
        13.2.3 Target Client
    13.3 Distributors/Traders List

14 Market Effect Factors Analysis
    14.1 Technology Progress/Risk
        14.1.1 Substitutes Threat
        14.1.2 Technology Progress in Related Industry
    14.2 Consumer Needs/Customer Preference Change
    14.3 Economic/Political Environmental Change

15 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2017-2022)
    15.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume, Revenue and Price Forecast (2017-2022)
        15.1.1 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate Forecast (2017-2022)
        15.1.2 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate Forecast (2017-2022)
        15.1.3 Asia-Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Price and Trend Forecast (2017-2022)
    15.2 Asia-Pacific R